Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.26 | N/A | -33.76% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.26 | N/A | -33.76% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about recent performance but remains committed to their strategic vision. They did not provide specific guidance for future quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite current setbacks.
The earnings report indicates that Arrowhead Pharmaceuticals is facing challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 1.53%, likely due to investor concerns over the company's current performance and lack of guidance. The absence of revenue figures adds to the uncertainty surrounding the company's financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Aug 4, 2025